Lucaseriksson9511

Patients with Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) frequently demonstrate coexistent AD neuropathological change (ADNC) and Lewy body pathology (LBP) at autopsy. We investigated the effects of ADNC and LBP on the clinical presentation of these patients.

We retrospectively compared clinical and pathological features of patients with different severity of ADNC and LBP. We also compared the burden of medullary LBP between patients with and without autonomic dysfunction.

Compared to pure ADNC, patients with AD/LBP have higher prevalence of DLB symptoms. Autonomic dysfunction strongly predicted the presence of LBP in patients with clinically diagnosed AD, but was not associated with increased LBP burden in the medulla. Severity of ADNC, but not LBP, was associated with cerebral atrophy.

Clinical presentation of patients with AD/LBP differs from patients with pure ADNC or LBP. selleck kinase inhibitor Autonomic dysfunction is a useful marker of otherwise unsuspected LBP.

Clinical presentation of patients with AD/LBP differs from patients with pure ADNC or LBP. Autonomic dysfunction is a useful marker of otherwise unsuspected LBP.

Participants from a longitudinal cohort study were surveyed to evaluate the practical feasibility of remote cognitive assessment.

All active participants/informants at the University of California San Diego Alzheimer's Disease Research Center were invited to complete a nine-question survey assessing technology access/use and willingness to do cognitive testing remotely.

Three hundred sixty-nine of 450 potential participants/informants (82%) completed the survey. Overall, internet access (88%), device ownership (77%), and willingness to do cognitive testing remotely (72%) were high. Device access was higher among those with normal cognition (85%) or cognitive impairment (85%) than those with dementia (52%), as was willingness to do remote cognitive testing (84%, 74%, 39%, respectively). Latinos were less likely than non-Latinos to have internet or device access but were comparable in willingness to do remote testing.

Remote cognitive assessment using interactive video technology is a practicable option for nondemented participants in longitudinal studies; however, additional resources will be required to ensure representative participation of Latinos.

Remote cognitive assessment using interactive video technology is a practicable option for nondemented participants in longitudinal studies; however, additional resources will be required to ensure representative participation of Latinos.

People with dementia (PWD) often become disoriented, which increases their risk of getting lost. This article explores the extent to which we can predict future whereabouts of PWD by learning from their past mobility patterns using Global Positioning System (GPS) tracking devices.

Seven older adults with dementia and eight healthy older adults completed 8 weeks of GPS data collection. We computed the probability that an appropriate algorithm can correctly predict the participant's future destinations using spatial and temporal patterns in each participant's GPS trajectories.

Relying on both spatial and temporal patterns, our results suggest that a 4-week record of mobility patterns displays 95% potential predictability across the dementia group, which is significantly higher than 92% potential predictability among the controls, t(13)=-3.39,

<.01, d=-1.75. That is, we can hope to be able to predict destinations of PWD about 95% of the time and destinations of controls about 92% of the time.

Our findings on predictability of mobility patterns among PWD offer new perspectives on predictive mobility models that can be used to locate missing persons with dementia.

Our findings on predictability of mobility patterns among PWD offer new perspectives on predictive mobility models that can be used to locate missing persons with dementia.

We aimed to assess episodic memory in genetic frontotemporal dementia (FTD) with the Free and Cued Selective Reminding Test (FCSRT).

The FCSRT was administered in 417 presymptomatic and symptomatic mutation carriers (181 chromosome 9 open reading frame 72 [

], 163 progranulin [

], and 73 microtubule-associated protein tau [

]) and 290 controls. Group differences and correlations with other neuropsychological tests were examined. We performed voxel-based morphometry to investigate the underlying neural substrates of the FCSRT.

All symptomatic mutation carrier groups and presymptomatic

mutation carriers performed significantly worse on all FCSRT scores compared to controls. In the presymptomatic

group, deficits were found on all scores except for the delayed total recall task, while no deficits were found in presymptomatic

mutation carriers. Performance on the FCSRT correlated with executive function, particularly in

mutation carriers, but also with memory and naming tasks in the

group. FCSRT performance also correlated with gray matter volumes of frontal, temporal, and subcortical regions in

and

, but mainly temporal areas in

mutation carriers.

The FCSRT detects presymptomatic deficits in

- and

-associated FTD and provides important insight into the underlying cause of memory impairment in different forms of FTD.

The FCSRT detects presymptomatic deficits in C9orf72- and MAPT-associated FTD and provides important insight into the underlying cause of memory impairment in different forms of FTD.

Genome-wide association studies (GWAS) for late onset Alzheimer's disease (AD) may miss genetic variants relevant for delineating disease stages when using clinically defined case/control as a phenotype due to its loose definition and heterogeneity.

We use a transfer learning technique to train three-dimensional convolutional neural network (CNN) models based on structural magnetic resonance imaging (MRI) from the screening stage in the Alzheimer's Disease Neuroimaging Initiative consortium to derive image features that reflect AD progression.

CNN-derived image phenotypes are significantly associated with fasting metabolites related to early lipid metabolic changes as well as insulin resistance and with genetic variants mapped to candidate genes enriched for amyloid beta degradation, tau phosphorylation, calcium ion binding-dependent synaptic loss,

-regulated inflammation response, and insulin resistance.

This is the first attempt to show that non-invasive MRI biomarkers are linked to AD progression characteristics, reinforcing their use in early AD diagnosis and monitoring.